The specific aim of this analysis was to evaluate the capability of a time and prostate-specific antigen (PSA) threshold model to prognosticate overall survival (OS) and disease-specific survival (DSS) based on early PSA kinetics after radiotherapy for prostate cancer by retrospective review of outcomes in 918 patients. Crossing below analyzed PSA thresholds at specific defined time points reduced disease-specific death hazard ratios to relative to the cohort above threshold. The time and PSA threshold model demonstrates the ability to prognosticate OS and DSS as early as 3 months post-radiotherapy for prostate cancer.
Introduction
Following the clinical acceptance of prostate-specific antigen (PSA) as a marker of biochemical tumor control, longitudinal assessment of PSA has become the dominant clinical tool for detecting treatment failure. 1, 2 Although the American Society of Radiation Oncology (ASTRO) consensus criteria delineate an accepted standard for biochemical tumor control, 3 several other distinct PSA models have demonstrated utility in prognosticating long-term treatment outcomes. [4] [5] [6] [7] [8] While the ASTRO consensus criteria requires a minimum observation period of 2 y, these techniques, which are based on the level of PSA nadir, time to PSA nadir, and absolute PSA thresholds, also require extended follow-up, limiting their clinical utility. 9, 10 We have recently demonstrated that time and PSA threshold modeling is effective in prognosticating probability of biochemical recurrence free survival (bRFS) as early as 3 months following curative intent external beam radiation therapy (EBRT). 11 The time and PSA threshold model stratifies patients based upon reaching or failing to reach given PSA thresholds by defined time parameters in follow-up, stratifying the analyzed population by a dichotomous variable at the same relative moment post-therapy.
Although bRFS is a widely used end point in both clinical research and practice, it represents an interim outcome, which necessitates correlation with definitive end points, such as overall survival (OS) and diseasespecific survival (DSS). 12 Therefore, it is desirable to determine if Time and PSA Threshold modeling can prognosticate eventual OS and DSS by analyzing the kinetics of PSA decline within the first year following EBRT. We have expanded and updated the available Cleveland Clinic Foundation database. Based on the previously established capability of this model to prognosticate long-term bRFS outcomes, we hypothesized that the model would also be prognostic of longterm OS and DSS.
Materials and methods
The Institutional Review Boards of the University of Texas Health Science Center at San Antonio (San Antonio, TX, USA) and the Cleveland Clinic Foundation (Cleveland, OH, USA) approved this retrospective chart review.
The studied population consisted of 918 patients treated between May 1987 and October 2001 at The Cleveland Clinic (Cleveland, OH, USA) by EBRT, without neo-adjuvant or planned adjuvant hormonal therapy. Patients in the series had a median T-classification T2a (range T1a-T3c), median Gleason sum 6 (range 4-10), median pretherapy PSA 8.5 ng/ml (range 1.1-692 ng/ml), and median of age 69 y (range 46-86 y).
EBRT was planned and delivered by conventional radiotherapy techniques (58.3%), 3D conformal radiotherapy (23.5%), and intensity-modulated radiation therapy (IMRT) (18.2%). Median prescription dose was 70.2 Gy (64.8-78 Gy) delivered in conventional fractionation (1.8-2 Gy/day), with the exception of those patients treated by IMRT, for whom fraction size was 2.5 Gy to prescription doses of 70 Gy.
The time and PSA threshold model assigns a binary (above or below) value for each patient with respect to a series of specific PSA thresholds and post-therapy time parameters. 11 The impact of falling below PSA thresholds of 3.0, 2.0, and 1.0 ng/ml, within 3, 6, and 12 months of follow-up with respect to OS and DSS was evaluated using Kaplan-Meier survival analysis with logrank Pvalues. Only PSA values obtained within the first year of follow-up were utilized for prognostic assessments in the present analysis. The median number of available PSA values obtained during the first year of follow-up was 3 (range 1-5 PSA values). Within 3, 6, and 12 months, 708, 807, and 877 patients had at least one PSA value available for analysis. Patients who did not have a PSA value documented for any of these time frames were excluded from analysis; patients that had PSA values drawn later than 3 and 6 months following EBRT were excluded from earlier time-point analysis.
Kaplan-Meier analysis was performed using either date of death (OS analysis) or date of disease-specific death (DSS analysis) as events. In subjects alive at the end of the observation period, the longest documented follow-up was entered as a censor in OS analysis. DSS analysis also used time of death from non-disease causes as a censor. Cox proportional hazard multivariate analysis was performed with T-classification (T1 vs T2a and higher), Gleason sum (o7 vs X7 and higher), and pretherapy PSA (o10 vs X10 ng/ml) as covariates. Statistical analyses were performed using JMP 5.01 statistical software (SAS Institute, Cary, NC, USA).
Results
The median length of post-EBRT follow-up available for survival analysis was 81 months (range 24-196 months) . During the observation period there were 192 deaths (20.9%), of which 49 were prostate cancer-related deaths (5.3%). Actuarial 5-and 10-y overall mortality was 9.5, and 33.7%, respectively. Actuarial disease-specific 5-y and 10-y mortality was 2.3, and 8.9%, respectively. Median time to death was 70 months (12-172 months) and median time to disease-specific death was 72 months (12-160 months).
Gleason sums of o7 and X7 were associated with 5-y DSS and OS of 99.0 vs 95.4% (Po0.0001) and 93.35 vs 85% (P ¼ 0.006), respectively. The 10-y DSS and OS were 94.8 vs 83.7% (Po0.0001) and 74.5 vs 56.4% (P ¼ 0.002), respectively. The disease-specific death hazard ratio for patients with Gleason sums of 7 or greater was 1.93 ( Figure 1) .
Pre-treatment PSA values 410 ng/ml and o10 ng/ml were correlated with 5-y DSS and OS of 96.0 vs 99.2% (Po0.0001), and 87.4 vs 93.1% (P ¼ 0.014), respectively. The 10-y DSS and OS in these populations were 84.8 vs 97.6% (Po0.0001), and 63.4 vs 68.7% (P ¼ 0.009), respectively. The disease-specific death hazard ration for the cohort of patients with pre-treatment PSA greater than 10 ng/ml was 2.08 ( Figure 1 ).
Tumor classification of T2a or greater vs T1c or less was correlated with 5-y DSS and OS of 96.9 vs 99.1% (Po0.004), and 88.6 vs 93.6% (P ¼ 0.003), respectively. The 10-y DSS and OS in these populations were 88.7 vs 96.1% (Po0.0018), and 62.6 vs 75.4% (P ¼ 0.0015), respectively. The disease-specific death hazard ration Figure 1 Cox proportional hazard analysis of disease-specific death for time and PSA threshold model parameter settings of 1.0, 2.0, and 3.0 ng/ ml at 3, 6, and 12 months of follow-up. For comparison, disease-specific death hazard ratios for established prognostic pretreatment patient characteristics (Gleason sum 46, pretherapy PSA 410, and T-classification higher T1c) are also displayed.
Time and PSA threshold modeling prognosticates prostate cancer OS and DSS SX Cavanaugh et al for the cohort of patients with tumor stage equal and higher than T2a was 1.91 ( Figure 1 ). Time and PSA threshold modeling using a combination of PSA thresholds of 1.0, 2.0, and 3.0 ng/ml and follow-up time frames of 3, 6, and 12 months as parameter settings exhibited prognostic potential with regard to DSS and OS. Multivariate analysis with Cox proportional hazard evaluation demonstrated statistical significance (defined as Po0.05) when pre-therapy patient characteristics and length of follow-up were used as covariates with time and PSA threshold variables (Figure 1) .
Depending on the time and PSA threshold parameter selected, Kaplan-Meier 10-y DSS estimates ranged between 77-88% and 93-99%, respectively, for patients above and below PSA thresholds at analyzed time points (Figure 2) . With regard to DSS, permutations of analyzed times and PSA thresholds yielded statistically significant survival differences (Po0.001-0.022), with the exception of combining the earliest time parameter with the lowest PSA threshold (PSA 1.0 ng/ ml at 3 months), which failed to reach statistical significance (P ¼ 0.078), due to a small cohort size (n ¼ 71) and a single event. Figure 2 Kaplan-Meier 10-y disease-specific and OS curves for patients below 1 ng/ml (A) or above 1 ng/ml (a), below 2 ng/ml (B) or above 2 ng/ml (b), or below 3 ng/ml (C) or above 1 ng/ml (c) at the time points specified. (Kaplan-Meier curves truncated to allow for ready visualization of survival differentials.)
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Comparative Kaplan-Meier 10-y OS estimates were 54-65% and 67-80%, respectively, for patients above and below PSA thresholds at analyzed time points (Figure 2 ). For OS, combinations of analyzed times and PSA thresholds yielded statistically significant differences between groups (Po0.001-0.046), again with the notable exception of the earliest time parameter (3 months), which failed to reach significance in combination with PSA thresholds of 2.0 and 3.0 ng/ml, respectively ( Table 1) .
The prostate cancer-specific death hazard ratio ranged from 0.38 to À0.81 for patients below the respective PSA thresholds at the analyzed time points when compared to patients above the threshold (Figure 1 ).
Conclusions
The utilization of PSA and PSA-based surrogate end points for mortality in cancer therapy of the prostate has become ubiquitous, although not without controversy. 10, [13] [14] [15] Using established PSA-based measures such as bRFS has significantly reduced the maturation time before results from clinical research are considered valid. However, the minimum 24-month follow-up required by the ASTRO consensus criteria 3 is still substantially longer than that might be desired, 16 although brief when compared to the time-frame required to derive mature OS and DSS data. Furthermore, even data that satisfy the minimum ASTRO consensus follow-up criteria are frequently subject to criticism. Consequently, efforts have been made to investigate potential surrogates that may be implemented earlier in post-therapy follow-up. [16] [17] [18] The use of a time and PSA threshold model has been previously demonstrated to prognosticate bRFS. 11 Our exploration of time and PSA threshold modeling was based upon the previous findings that crossing post-EBRT PSA threshold values of 1.0 and 0.5 ng/ml, irrespective of ultimate nadir, was correlated with improved outcomes, 19, 20 along with the observation that combining a PSA threshold with a time component yielded a greater prognostic potential than the simple observation that a PSA decline had occurred. 19 Using parameters similar to ones used in the present study, we demonstrated that long-term bRFS could be prognosticated as early as 3 months following completion of EBRT. In the previous analysis, we noted the superior utility of comparatively higher PSA thresholds (eg 1.0, 2.0, and 3.0 ng/ml) for prognosticating biochemical failure early in follow-up, primarily due to the limited numbers of patients observed to cross lower PSA thresholds (eg 0.5 and 0.2 ng/ml) within the first year following EBRT in the analyzed database. Similar absolute differences in long-term bRFS were observed between PSA threshold cohorts defined at time points ranging from 3 to 60 months post-radiotherapy. Owing to the observation in this earlier analysis that no increased prognostic utility was gained by increased follow-up time, early time points, within the first year following EBRT, were explored in the present analysis.
Employing this time and PSA threshold model to analyze if such an approach can also prognosticate longterm OS and DSS, we have shown that eventual differences in OS and DSS could be prognosticated as early as 3 months following EBRT for prostate cancer. As with other studies of prostate cancer outcomes, analysis of OS is confounded by non-cancer-related deaths during 21 We interpret the present findings as supportive of the utility of the employed time and PSA threshold model as a 'responseto-treatment metric', inferring a higher likelihood of survival upon those patients who reach lower PSA thresholds earlier in follow-up.
The specific clinical applicability of this response-totreatment metric must be elucidated prior to endpoint surrogate usage in clinical trial settings. 15 Pending verification of the results derived from single institution data in an independent and preferable prospectively established database, this model may ultimately serve to identify those patients or cohorts more likely to benefit from adjuvant hormonal therapy, because the probability of DSS and OS may be modeled as a timedependent function of remaining above given PSA thresholds (Figure 3) . Utilizing the presented time and PSA threshold model, it may become reasonable to stratify patients remaining above a PSA of 1.0 ng/ml at 1 y of follow-up to receive adjuvant hormonal therapy as they appear to be at high-risk for disease-specific mortality.
While we propose the validity of this model to serve as a response-to-treatment metric, prospectively collected randomized data will be required in order to assess the acceptability of the model's validity to represent a new surrogate for treatment outcomes in prostate cancer phase III clinical trials. In the interim, the clinical usefulness of the proposed model may actually be further explored as it has been suggested that the satisfaction of rigorous criteria as suggested by Prentice 22 is not required in order for a model to serve as a surrogate in applications other than phase III trials. 14, [23] [24] [25] [26] According to previously published findings and the present analysis, time and PSA threshold modeling appears to be a valid response-to-treatment metric, prognosticating not only bRFS, but also the ultimate outcome measures DSS and OS, as early as 3 months following external beam radiation therapy for prostate cancer. Validation of conclusions derived from this large single-institution prostatic carcinoma follow-up database in an independent population will be required to establish the model as a response-to-treatment metric which may assist clinicians in determining which patients should be considered for early adjuvant therapy. Ultimately, satisfaction of established surrogacy criteria will be needed to define the validity of time and PSA threshold modeling as evaluative criteria of experimental arms in phase III studies.
